ETON
NASDAQ · Pharmaceuticals
Eton Pharmaceuticals Inc
$56.46
+9.31 (+19.75%)
Financial Highlights (FY 2026)
Revenue
85.80M
Net Income
-4,937,926
Gross Margin
53.5%
Profit Margin
-5.8%
Rev Growth
+55.5%
D/E Ratio
1.17
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 53.5% | 53.5% | 34.9% | 34.9% |
| Operating Margin | -1.1% | -1.0% | 14.4% | 15.1% |
| Profit Margin | -5.8% | -5.5% | 13.3% | 11.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 85.80M | 55.17M | 122.17M | 107.30M |
| Gross Profit | 45.87M | 29.49M | 42.65M | 37.45M |
| Operating Income | -909,496 | -526,294 | 17.64M | 16.16M |
| Net Income | -4,937,926 | -2,857,412 | 16.25M | 12.60M |
| Gross Margin | 53.5% | 53.5% | 34.9% | 34.9% |
| Operating Margin | -1.1% | -1.0% | 14.4% | 15.1% |
| Profit Margin | -5.8% | -5.5% | 13.3% | 11.8% |
| Rev Growth | +55.5% | +55.5% | -8.5% | +2.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 439.25M | 439.25M | 24.71M | 28.65M |
| Total Equity | 375.94M | 375.94M | 125.41M | 143.27M |
| D/E Ratio | 1.17 | 1.17 | 0.20 | 0.20 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 3.43M | 2.10M | 25.36M | 21.76M |
| Free Cash Flow | — | — | 11.15M | 16.18M |